Not Yet Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) - CA244-0010
Mis à jour: 14 août, 2025 | ClinicalTrials.gov
Phase
Sexe(s)
Tranche d’âge
Emplacement(s)
Not Yet Recruiting
Inclusion Criteria: - Non-squamous NSCLC, not amenable to treatment in curative intent. - Documented evidence of EGFR mutation (exon 19 deletion, L858R mutation). - Progressive disease on a 3rd-generation (such as osimertinib, furmonertinib, lazertinib,...) EGFR-TKI-based mono- or combination therapy regimen as the most recent line of therapy in an adjuvant, locally advanced, or metastatic treatment setting. - Eligible to receive a platinum-based doublet chemotherapy regimen (either cisplatin or carboplatin in combination with pemetrexed). Exclusion criteria: - Inadequate organ function and/or bone marrow reserve. - Leptomeningeal metastases or spinal cord compression. - Poorly controlled systemic medical conditions. - Other protocol-defined inclusion/exclusion criteria apply.
Nous vous recommandons fortement de contacter BMS pour signaler les effets secondaires (événements indésirables).
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici.
Signaler des effets secondaires (effets indésirables) ou des plaintes concernant la qualité du produit: Informations médicales
